Abbott and Google are partnering to combine Abbott's over-the-counter Lingo glucose sensor with Google's AI technology and Health app, starting with integrations later this year.
The collaboration includes a large real-world metabolic health study that will help Google's AI-powered health coach deliver personalized recommendations based on continuous glucose data alongside activity, sleep, and wearable information.
The effort aims to help people proactively manage their metabolic health by understanding how daily habits affect blood sugar levels.
What happened
Abbott and Google announced a multiyear partnership to integrate Abbott's Lingo glucose sensor with Google's AI and Health app, beginning with Lingo integrations into Google Health later this year. The companies plan to launch a large metabolic health study combining continuous glucose, wearable, laboratory, and survey data.
Why it matters
The partnership makes glucose insights more accessible and actionable for people managing metabolic health. Google's AI-powered health coach—available to Google Health premium subscribers—will use the integrated data to provide personalized recommendations based on how daily habits like diet and exercise affect blood sugar levels. Abbott's Lingo sensor, an over-the-counter device that debuted in the U.S. in 2024, reaches adults not taking insulin who want to understand their metabolic patterns.
What to watch
Results from the planned metabolic health study, which will integrate data across glucose readings, wearables, labs, and surveys. These findings are expected to inform more personalized guidance and help both companies improve their products. Abbott did not disclose the study enrollment size.
Ask the AI about this article →
The partnership reflects a broader convergence of consumer health monitoring and AI-driven personalization. Google's Health app, built on its 2021 acquisition of Fitbit for $2.1 billion, has positioned the company to integrate wearable and health data at scale. By connecting Abbott's glucose sensor to this ecosystem, the companies can offer users a more complete picture of metabolic health—linking continuous glucose readings to activity, sleep, and other behavioral data. The planned large-scale metabolic health study underscores the strategic value both companies see in real-world evidence: Abbott gains validation and product improvement insights for Lingo, while Google obtains training data and health outcomes that can refine its AI coaching capabilities.
This move arrives as competitors pursue similar integrations. Dexcom, Abbott's rival in continuous glucose monitoring, is participating in a Food and Drug Administration pilot program to test an AI-enabled glucose health program designed to help users improve glycemic control and lower blood sugar levels. The trend suggests that standalone glucose sensors are increasingly becoming entry points for broader digital health platforms, where AI recommendations and personalized insights drive engagement and retention among users managing metabolic conditions.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
A UK study by UK AI Security Institute and Limbic AI surveyed 6,474 British adults
Broadcom's Clayton Donley says companies are doing mission-critical work with AI agents quickly, but without t…
OpenAI released a new evaluation framework on July 17, 2026, urging companies to measure AI ROI by 'useful out…
As AI agents perform real business tasks, 'Agentic Identity' (giving each AI a unique employee-like ID) and 'D…
The European Union is expanding regulation of ChatGPT and will mandate protections for minors
